GoAI
Get started
Evaxion Biotech A/S logo

Evaxion Biotech A/S

EVAX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.31

+$0.03 · +0.91%

Aug 21, 4:00 PM ET

EVAX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

94

Deep Value

Momentum

18

Strong Down

Sentiment

41

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

Industry
Biotechnology
Sector
Healthcare
Headquarters
DK
CEO
Helen Katrina Tayton-Martin
Listed since
Feb 5, 2021
Employees
46

Market position

Day range

Current $3.31

52-week range

Current $3.31

Open
$3.31
Previous close
$3.28
Volume
540.83K
5.65× average
Average volume
95.65K
Average daily volume
Market cap
20.91M USD
Beta
0.26
Market reference 1
50-day average
$3.1466
+5.19% above average
200-day average
$4.0614
-18.50% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.54×
P/B (TTM)
0.14×
P/S (TTM)
2.79×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-115.98%
Net margin
-115.49%

Financial health

Debt / equity
0.75×
Altman Z-score
-8.89
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3151%-9052%-21255%-33458%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2023: -30406.85%Operating margin, FY2024: -440.55%Operating margin, FY2025: -122.66%Net margin, FY2023: -30308.22%Net margin, FY2024: -316.00%Net margin, FY2025: -102.38%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2023 -30406.85%. Operating margin FY2024 -440.55%. Operating margin FY2025 -122.66%. Net margin FY2023 -30308.22%. Net margin FY2024 -316.00%. Net margin FY2025 -102.38%.

Income trends

Revenue

7.53M USD+125.12%

Operating income

−9.23M USD+37.32%

Net income

−7.71M USD+27.07%
Income trends across reported periods10.86M USD−2.48M USD−15.83M USD−29.17M USDRevenue, FY2023: 73K USDRevenue, FY2024: 3.34M USDRevenue, FY2025: 7.53M USDOperating income, FY2021: −25.83M USDOperating income, FY2022: −25.26M USDOperating income, FY2023: −22.2M USDOperating income, FY2024: −14.73M USDOperating income, FY2025: −9.23M USDNet income, FY2021: −24.53M USDNet income, FY2022: −23.17M USDNet income, FY2023: −22.13M USDNet income, FY2024: −10.57M USDNet income, FY2025: −7.71M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 73K USD. Revenue FY2024 3.34M USD. Revenue FY2025 7.53M USD. Operating income FY2021 −25.83M USD. Operating income FY2022 −25.26M USD. Operating income FY2023 −22.2M USD. Operating income FY2024 −14.73M USD. Operating income FY2025 −9.23M USD. Net income FY2021 −24.53M USD. Net income FY2022 −23.17M USD. Net income FY2023 −22.13M USD. Net income FY2024 −10.57M USD. Net income FY2025 −7.71M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue7.53M USD3.34M USD73K USD——
Gross profit7.53M USD3.34M USD73K USD——
Research and development9.98M USD10.46M USD11.92M USD17.06M USD19.58M USD
Selling, general, and administrative6.49M USD7.32M USD10.08M USD8.06M USD6.18M USD
Operating expenses16.76M USD18.08M USD22.27M USD25.26M USD25.83M USD
Interest income299K USD254K USD154K USD2.83M USD2.04M USD
Interest expense876K USD962K USD897K USD1.51M USD915K USD
Depreciation and amortization615K USD607K USD615K USD571K USD344K USD
Operating income−9.23M USD−14.73M USD−22.2M USD−25.26M USD−25.83M USD
Net income−7.71M USD−10.57M USD−22.13M USD−23.17M USD−24.53M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 3 misses, 3 met estimates
Average EPS surprise
-74.27%
11 comparable reports
Latest EPS result
-0.01
Estimate -0.01 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.28-1.04-2.35-3.67Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MetQ3 '26MetQ4 '26Estimate
Q1 2025, reported Mar 26, 2025: actual -3.4, estimate -0.26, surprise -1207.69%, Miss. Q2 2025, reported May 27, 2025: actual -0.29, estimate -0.65, surprise +55.38%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.76, estimate -0.5, surprise -52.00%, Miss. Q4 2025, reported Oct 30, 2025: actual 0.01, estimate -0.01, surprise +200.00%, Beat. Q1 2026, reported Mar 5, 2026: actual -0.02, estimate -0.245, surprise +91.84%, Beat. Q2 2026, reported May 26, 2026: actual -0.01, estimate -0.01, surprise 0.00%, Met estimate. Q3 2026, reported Aug 13, 2026: actual -0.01, estimate -0.01, surprise 0.00%, Met estimate. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.01, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates9.93M6.63M3.33M31.45KQ1 '25MissQ2 '25EstimateQ3 '25MissQ4 '25BeatQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 26, 2025: actual 122K USD, estimate 1.66M USD, surprise -92.65%, Miss. Q2 2025, reported May 27, 2025: actual —, estimate 60K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 37K USD, estimate 8M USD, surprise -99.54%, Miss. Q4 2025, reported Oct 30, 2025: actual 7.49M USD, estimate 3.75M USD, surprise +99.79%, Beat. Q1 2026, reported Mar 5, 2026: actual —, estimate 7.5M USD, surprise —, Comparison unavailable. Q2 2026, reported May 26, 2026: actual —, estimate 9.2M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual —, estimate 6.7M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 5, 2026: actual —, estimate 300K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy4100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions

EVAX news

seekingalpha.com

Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript

Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

Evaxion announces business update and second quarter 2026 financial results

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and…

Read source
globenewswire.com

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program

COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it pipeline of cancer vaccine…

Read source
globenewswire.com

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and…

Read source
globenewswire.com

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical…

Read source
globenewswire.com

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting…

Read source

Corporate actions

Corporate action history

Stock split

Effective Jan 14, 2025

1:5

Stock split

Effective Jan 22, 2024

1:10

EVAX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research EVAX

research.disclaimer